IFN- Arm. Disease Course and Evolution of the Patients Who Achieved a Cytogenetic Response (Ph neg metaphases ≥33%)
| Best Cytogenetic Response (Ph neg metaphases) . | Complete (100%) . | Major (66%-99%) . | Minor (33%-65%) . | Total (33%-100%) . |
|---|---|---|---|---|
| No. of cases | 23 | 23 | 24 | 70 |
| Allogeneic BMT | 0 | 5 | 2 | 7 |
| Remaining | 23 | 18 | 22 | 63 |
| Dead, accelerated or blastic phase | 3 (13%) | 7 (39%) | 15 (68%) | 25 (40%) |
| Dead, chronic phase | 3 (13%) | 1 (5%) | 0 | 4 (6%) |
| Alive, chronic phase | 17 (74%) | 10 (55%) | 7 (32%) | 34 (54%) |
| Discontinued IFN-α before progression | 0/23 | 3/18 (17%) | 9/22 (41%) | 12/63 (19%) |
| Best Cytogenetic Response (Ph neg metaphases) . | Complete (100%) . | Major (66%-99%) . | Minor (33%-65%) . | Total (33%-100%) . |
|---|---|---|---|---|
| No. of cases | 23 | 23 | 24 | 70 |
| Allogeneic BMT | 0 | 5 | 2 | 7 |
| Remaining | 23 | 18 | 22 | 63 |
| Dead, accelerated or blastic phase | 3 (13%) | 7 (39%) | 15 (68%) | 25 (40%) |
| Dead, chronic phase | 3 (13%) | 1 (5%) | 0 | 4 (6%) |
| Alive, chronic phase | 17 (74%) | 10 (55%) | 7 (32%) | 34 (54%) |
| Discontinued IFN-α before progression | 0/23 | 3/18 (17%) | 9/22 (41%) | 12/63 (19%) |
The proportion of the patients who progressed and died in accelerated or blastic phase was significantly related with the cytogenetic response (P = .005, chi-square test).